A number of clinical placebo controlled trials have been conducted with simple probably finely dispersed palmitoylethanolamide, without any high tech micronization process. These trials have documented in more than 3000 patients that simple fine PEA is effective and safe in states of inflammation, prophylaxis and chronic pain.
Further placebo-controlled studies using formulations such as modern micronized and ultra-micronzed PEA have been published and these support the use of such formulations, mostly in peripheral pains (micronized) and in central sensitization.
The discussion in the literature is difficult to follow, but most probably it does not matter for patients what formulation is used, but is is quite important that:
1. PEA is produced in a standardized way, preferably via a patented method,
2. PEA is pro-analyse and pure, and documented purity of its ingredient via Certificate of Analysis is also recommended.
Most probably only the patent protected products of een Italiaans bedrijf and Russell Science will comply with such requirements ( PeaVera and PeaPure).
1. Kriek R. Marketing messages in pharmacological papers and scientific chapters: The case of palmitoylethanolamide and its formulations.
Pharmacol Res. 2014 Apr 24. pii: S1043-6618(14)00047-4. doi: 10.1016/j.phrs.2014.04.007. [Epub ahead of print] No abstract available.
2. Kriek R. Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives. Inflammopharmacology. 2014 Mar 20. [Epub ahead of print]